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Abstract
Numerous experimental researches and clinical observations reveal that immediately after
cardiac arrest a significant platelet activation appears which is not counterbalanced by endog-
enous fibrinolysis and leads to disseminated laying down of fibrin’s concrement in arteria and
microclots’ formation. The process is being developed during cardiopulmonary resuscitation
and extended to a post-resuscitation period. There have been some experimental works and
clinical examinations revealing that treatment with heparin and thrombolysis’ application can
increase the survival rate after an incident of cardiac arrest. Thrombolysis therapy becomes
a new method facilitating prognosis as to patient’s health after cardiac arrest. Presently one
can state undoubtedly that either fibrinolysis therapy or thrombolysis therapy is justified at
suspicion of an acute pulmonary embolism contributing to patient’s hemodynamic
stabilization. In the results it has been obtained hitherto that this sort of therapy, applied
during cardiopulmonary resuscitation after prolonged cardiac arrest at acute coronary syn-
drome increases survival rate and improves patient’s neurological state during a post-resusci-
tation period. Full confirmation of these observations needs some further multi-centered,
randomized studies of the issues under consideration. (Cardiol J 2007; 14: 24–28)
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Introduction
Disorders of microcirculation that begin imme-
diately after cardiac arrest and evolve during cardi-
opulmonary resuscitation are among the most im-
portant causes of adverse prognosis of patients af-
ter the return of spontaneous circulation. In the
postresuscitation period, inefficiency of peripheral
perfusion with limited blood volume and impaired
heart contractility is caused not only by the lack of
adaptation of cardiac output and vascular resistance
of pulmonary and systemic circulation but also by
coagulation disturbances [1, 2]. Periodic lack of flow
causes endothelial dysfunction and activation of
homeostasis resulting in platelet clots and throm-
bus formation which in turn cause abrupt occlusion
of many small vessels. Thus organ perfusion is not
preserved in spite of correct values of systemic
hemodynamic parameters (“no-reflow phenome-
non”) [3]. The most important endpoint of resusci-
tation is the return of proper function of central
nervous system, otherwise preservation of other
organ function is only secondary [4].
Searching for methods which increase the ef-
ficacy of resuscitation procedures is an important
direction of scientific studies. These are aimed at
potential improvement of tissue perfusion during
resuscitation and limitation of results of reperfusion
after the return of spontaneous circulation. Apart
from moderate hypothermia, currently there is no
available method substantially improving neurolog-
ical status after cardiac arrest [5]. The effects of
thrombolysis are very promising [6, 7]. Thrombolytic
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therapy during resuscitation is aimed at restoration
of flow in the vessels of coronary or pulmonary cir-
culation, occlusion of which could lead to cardiac
arrest, but at the same time it helps to prevent for-
mation of many small thrombi in the vessels of im-
portant organs.
Experimental studies and clinical trials to date
have demonstrated that consequences of coagulation
disturbances emerging immediately after cardiac
arrest could be reversible with thrombolytic thera-
py, if it was started immediately. Because currently
there is no absolute contraindication for such thera-
py, the decision of its initiation should be based on




The coagulation and fibrynolysis processes are
influenced by many general and local conditions,
related to flow regulation, and later reperfusion,
including hypoxemia, ischemia, catecholamine and
free radicals release.
In experimental and clinical studies major co-
agulation disturbances emerging during cardiac ar-
rest were demonstrated [8]. Disseminated intravas-
cular coagulation with thrombi formation and fibrin
deposition in microcirculation leads to multi-organ
damage [9].
In the experimental model, directly after car-
diac arrest and later during resuscitation proce-
dures, activation of coagulation was observed, in-
volving exogenous as well as endogenous pathway.
Its consequence is microthrombosis of capillaries
in the brain, lungs and kidneys [10]. In animal stud-
ies, multiple microthrombi in brain vessels and dis-
seminated intravascular coagulation were demon-
strated as early as 5 min from cardiac arrest into
cardiopulmonary resuscitation. Clots were ob-
served in large arteries after 20 min from the re-
turn of spontaneous circulation in normothermy and
after 40 min, when cardiac arrest was induced in
hypothermic conditions [11]. Gross and microscopic
specimen of brain vessels showed the presence of
clots shortly after cardiac arrest. It was proved that
activation of coagulation and platelets not only in-
tensify early disorders of brain perfusion and “no-
reflow” phenomenon, but also cause late hypoper-
fusion [12].
The first paper which demonstrated sudden
activation of coagulation during postresuscitation
period in humans was published in 1995 [9]. The
significant activation of coagulation leading to
trombin formation (with increasing concentration of
soluble fibrin monomers that indicates systemic, not
only local creation) was observed in patients under-
going cardiopulmonary resuscitation and after re-
turn of spontaneous circulation. Activation of plas-
ma coagulation factors and platelets in the pos-
tresuscitation period observed in clinical conditions
was significant and resulted in fibrin deposition and
microthrombi developing in the vessels [9]. It is
known, that concentration of white blood cells and
intravascular coagulation triggered with platelet
aggregation may lead to microcirculation disorders
[13, 14].
Conversion of fibrinogen to fibrin leads to in-
crease of plasma thrombin — antithrombin (TAT)
complex in patients after cardiac arrest. Significant
increase of TAT concentration is followed by a de-
crease of anticoagulant factors like active S and C
proteins [8]. Activation of C protein warrants natu-
ral balance, physiologically suppressing activation
of coagulation and inflammatory reaction. In clini-
cal studies increased, endogenous activation of C
protein was observed only in very short period af-
ter out of hospital cardiac arrest. Although fibrin
creation and sudden endothelial stimulation in the
early periresuscitation period initially facilitate ac-
tivation of C protein, maintaining this process is
complicated by progressively developing endothe-
lial dysfunction [15]. Based on experimental model
of ischemic brain and spinal cord damage it was
proved that exogenous active C protein may mini-
mize results of ischemic and postreperfusion dam-
age in the nervous system [16].
Increased activity of tissue plasminogen acti-
vator which was demonstrated directly after return
of spontaneous circulation decrease during next
24 h and is practically irrelevant, while the activity
of inhibitor of plasminogen activator is significantly
increased and in consequence leads to progressive
unlimited trombin generation. Also during later pos-
tresuscitation period, despite progressive intravas-
cular coagulation, still no increase of concentration
of the coagulation inhibitors is observed [17]. Thus
the majority of patients develop inhibition of fibri-
nolysis, which is physiologically accompanied by
coagulation. It can be due to increasing concentra-
tion of PAI-1, which increases even more during
early postresuscitation period [17].
These data confirm activation of coagulation
during postresuscitation period, with activation of
endogenous fibrinolysis accompanying only in the
early period after cardiac arrest. This leads to hae-
mostatic disequilibrium, and, in consequence, to
microthrombosis and microcirculation disorders [18].
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Significant activation of platelet aggregation without
simultaneous activation of prostaglandin I and F syn-
thesis during periresuscitation period, not sufficient-
ly balanced by endogenous fibrinolysis, is an addi-
tional factor of uncontrolled blood coagulation [13].
Effects of thrombolytic therapy during
cardiac arrest caused by acute coronary
syndrome or massive pulmonary embolism
Acute pulmonary embolism or myocardial inf-
arction are the cause of cardiac arrest in 50–70% of
patients. Thombolytic therapy during acute coro-
nary syndrome is an alternative to percutaneous
coronary angioplasty. Prompt admission allows for
early opening and maintenance off low in the cul-
prit artery. In the group of 681 resuscitated patients
after cardiac arrest during myocardial infarction, in
308 fibrinolysis was administered, resulting in lower
in-hospital mortality (48% vs. 62%) [19]. Other stud-
ies of patients after cardiac arrest related to myo-
cardial infarction treated with thrombolysis demon-
strated better prognosis without excess major
bleeding complications [20].
Pulmonary embolism is common in hospital-
ized patients with mortality rate of only 0.4% [21].
But massive pulmonary embolism is the second
most often cause of nontraumatic cardiac arrest. In
45–90% of patients who died of pulmonary embo-
lism, cardiac arrest occurred after 1–2 h from symp-
tom onset [21]. Experience indicates that classic
cardiopulmonary resuscitation in such cases is rare-
ly successful without treatment like pulmonary
embolectomy or thrombolysis administered early.
Immediate pulmonary embolectomy is not possible
in most cases because of logistic reasons. Alterna-
tive therapy, available even in out-of-hospital con-
ditions, is thrombolysis [22]. According to some
authors pulmonary embolism as a presumed cause
of cardiac arrest is an agreed indication for throm-
bolytic agent administration. It should be underlined
that possible misdiagnosis of myocardial infarction
when pulmonary embolism was the cause did not
worsen the prognosis if thrombolytic agents were
administred [22].
Estimation of effects of thrombolytic
therapy during out-of-hospital
nontraumatic cardiac arrest
Numerous case reports or studies including
small number of patients indicate that thrombolyt-
ic therapy used as ultima ratio (when the only oth-
er possible solution would be termination of cardio-
pulmonary resuscitation) improves outcome in the
group of resuscitated patients [23]. Evidence for
efficacy of out-of-hospital thrombolysis justify at-
tempting such therapy in patients with out-of-hos-
pital nontraumatic cardiac arrest of unknown etio-
logy. There are numerous case reports pointing to
increasing success rate of cardiopulmonary resus-
citation by additional administration of fibrino- or
thrombolytic therapy [23]. First study which proved
efficacy of thrombolytic therapy in a patients with
prolonged cardiopulmonary resuscitation per-
formed after out-of-hospital cardiac arrest was pub-
lished only in 2001 [24]. It included 90 patients af-
ter cardiac arrest probably related to myocardial
infarction or pulmonary embolism without contrain-
dication to thrombolytic therapy. In case 15 min
standard cardiopulmonary resuscitation was ineffec-
tive, 50 mg rt-PA and 5000 U of unfractioned
heparin were administered. If there was no return
of spontaneous circulation after next 30 min, the
doses of the drugs were repeated. In 40 patients in
whom thrombolytic therapy was administered, the
return of spontaneous circulation was achieved in
68% (vs. 48% in the group not treated with rt-PA).
Thirty five percent of patients survived first 24 h,
compared to 22% in the group not treated with rt-PA,
and 15% of patients receiving rt-PA were discharged
from hospital (vs. 8% in group without rt-PA). There
were no major bleeding complications related direct-
ly to cardiopulmonary resuscitation [24].
Another large prospective study included
233 patients with pulseless electrical activity (PEA)
cardiac arrest [25]. During cardiopulmonary resus-
citation, standard cardiopulmonary resuscitation
was used with or without additional 15-min infusion
of 10 mg rt-PA. In contrast to other studies per-
formed so far, this study did not show beneficial
effect in the rt-PA group (21.4%) over placebo
(23.3%) [25]. But this study was vividly criticized
because of methodological defects [26]. Interesting
results were obtained in a large group of 13000 pa-
tients with myocardial infarction. Two subgroups
were compared: one group of 303 patients after
cardiac arrest who did not receive thrombolysis
during cardiopulmonary resuscitation and another
group of 67 patients who had received thromboly-
sis after the return of spontaneous circulation [27].
It was proved that cerebral damage during perire-
suscitation period occurs only in 9% patient treat-
ed with thrombolytic agents compared to 40% of
untreated patients [27].
In clinical studies to date no significant increase
in frequency of major bleeding complications after
administration of thrombolytic therapy in patients
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during cardiac arrest was found [23]. Analysis of all
published papers evaluating effects of fibrinolysis
during cardiopulmonary resuscitation did not point
to increased risk of bleeding complications com-
pared to standard therapy [7]. Moreover, good neu-
rological status of patients receiving thrombol-
ysis was emphasized [6, 28]. There was no in-
creased frequency of other complications like
rupture of aortic aneurysma, cardiac tamponade or
pleural heamatoma [29]. Several authors suggest
that in some situations with no alternative treat-
ment, when standard resuscitation is unsuccessful,
possible contraindications to fibrinolysis/thrombol-
ysis should be treated as relative or even ignored
in individual cases [6].
Thrombolytic therapy which is accepted in pa-
tients with cardiac arrest related to pulmonary
embolism or myocardial infarction is not regarded
as standard during cardiopulmonary resuscitation [30].
The main reason is not the lack of efficacy of such
therapy in nontraumatic cardiac arrest but fear of
bleeding complications that may follow, related to
drug properties and mechanical injuries resulting
from cardiopulmonary resuscitation. Growing
number of reports concerning safety of thrombolytic
therapy during cardiopulmonary resuscitation in
patients with massive pulmonary embolism and
myocardial infarction show beneficial effect on he-
modynamic stabilization after restoration of spon-
taneous circulation and improved prognosis, sug-
gesting serious consideration of such treatment in
every case of nontraumatic cardiac arrest. Despite
available evidence suggesting beneficial effect of
thrombolytic therapy during cardiopulmonary resus-
citation it can not be unambiguously stated whether
the benefit relates to higher survival rate only or to
improvement of neurological status as well (what was
demonstrated in experimental and clinical works to
date) [6, 28]. Hence, much hope is elicited in rela-
tion to forthcoming results of a large prospective,
multicenter, randomized and controlled trial estimat-
ing efficacy and safety administration of thrombolytic
therapy during cardiopulmonary resuscitation —
TROICA (Thrombolysis In Cardiac Arrest).
References
1. Mysiak A. Zaburzenia hemodynamiczne i stężenie
b-endorfiny w surowicy u chorych we wczesnym okre-
sie poresuscytacyjnym. Folia Cardiol, 2001; 5: 527–535.
2. Mysiak A, Kobusiak-Prokopowicz M. The assess-
ment of the haemodynamic disturbances in patients
in the early postresuscitation period. Resuscitation,
2004; 62: 406.
3. Böttiger BW, Polarz H, Mysiak A, Spöhr F. Czy
zaburzenia krzepnięcia w okresie poresuscytacyjnym
mają znaczenie kliniczne? In: Kubler A, Mysiak A
ed. Choroba poresucytacyjna. Urban & Partner,
Wrocław 2005: 137–152.
4. Mysiak A. Czynniki determinujące przeżywalność
chorych we wczesnym okresie poresuscytacyjnym.
In: Kubler A, Mysiak A ed. Choroba poresucytacyj-
na. Urban & Partner, Wrocław 2005: 41–50.
5. Nolan JP, Morley PT, Vanden Hoek TL et al. Thera-
peutic hypothermia after cardiac arrest: An Advisory
Statement by the Advanced Life Support Task Force
of the International Liaison Committee on Resusci-
tation. Circulation, 2003; 108: 118–121.
6. Böttiger BW, Martin E. Thrombolytic therapy dur-
ing cardiopulmonary resuscitation and the role of co-
agulation activation after cardiac arrest. Curr Opin
Crit Care, 2001; 7: 176–183.
7. Spöhr F, Böttiger BW. Safety of thrombolysis during
cardiopulmonary resuscitation. Drug Safety, 2003;
26: 367–379.
8. Adrie Ch, Laurent I, Monchi M, Cariou A, Dhainaou J-F,
Spauulding Ch. Postresuscitation disease after cardi-
ac arrest: a sepsis –like syndrome? Curr Opin Crit
Care, 2004; 10: 208–212.
9. Boettiger BW, Motsch J, Boehrer H et al. Activation
of blood coagulation after cardiac arrest is not ba-
lanced adequately by activation of endogenous
fibrynolysis. Circulation, 1995; 92: 2572–2578.
10. Gaszyński W: Research work on blood clotting sys-
tem during cardiopulmonary resuscitation. Anaesth
Resus Inten Therapy, 1974; 2: 303–316.
11. Tisherman S, Chabal C, Safar P, Stezoski W. Resus-
citation of dogs from cold-water submersion using
cardiopulmonary bypass. Ann Emerg Med, 1985; 14:
389–396.
12. Boettiger BW, Fischer MS, Hossman KA. Throm-
bolysis during cardiopulmonary resuscitation de-
creases the cerebral ”no-reflow phenomenon” in
cats. Ann Hematol, 1994; suppl. 2: S72.
13. Bottiger BW, Bohrer H, Boker T, Motsch J,
Aulmann M, Martin E. Platelet factor 4 release in
patients undergoing cardiopulmonary resuscitation-
can reperfusion be impaired by platelet activation?
Acta Anaesthesiol Scand, 1996; 40: 631–665.
14. Gando S, Kameue T, Nanzaki S, Igarashi M, Nakanishi Y.
Platelet activation with massive formation of throm-
boxane A2 during and after cardiopulmonary resusci-
tation. Intensive Care Med, 1997; 23: 71–76.
15. Faust SN, Levin M, Harrison OB et al. Dysfunction
of endothelial protein C activation in severe menin-
gococcal sepsis. N Engl J Med, 2001; 345: 408–416.
16. Taoka Y, Okajima K, Uchiba M et al. Activated pro-
tein C reduces the severity ol compression-induced
28
Cardiology Journal 2007, Vol. 14, No. 1
www.cardiologyjournal.org
spinal cord injury in rats by inhibiting activation of
leukocytes. J Neurosci, 1998; 18: 1393–1398.
17. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Mas-
sive fibrin formation with consecutive impairment of
fibrinolysis in patients with out-of-hospital cardiac
arrest. Thromb Haemost, 1997; 77: 278–282.
18. Boettiger BW, Kern S, Glaetzer R et al. Thrombolysis
after unsuccessful CPR. Resuscitation, 1998; 37: S48.
19. Schiele R, Rustige J, Burcyk U et al.; for the ALKK
Study Group: Thrombolysis after resuscitation in
acute myocardial infarction. J Am Coll Cardiol, 1996;
27 (suppl.): 279A.
20. Tenaglia AN, Califf RM, Candela RJ et al. Thrombo-
lytic therapy in patients requiring cardiopulmonary
resuscitation Am J Cardiol, 1991; 68: 1015–1019.
21. Stein PD, Henry JW. Prevalence of acute pulmonary
embolism among patients in a general hospital and at
autopsy. Chest, 1995; 108: 978–981.
22. Bottiger BW, Reim SM, Diezel G, Bohrer H, Martin E.
High-dose bolus injection of urokinase. Use during
cardiopulmonary resuscitation for massive pulmo-
nary embolism Chest, 1994; 106: 1281–1283.
23. Tiffany PA, Schultz M, Stueven H. Bolus thrombo-
lytic infusions during CPR for patients with refracto-
ry arrest rhythms: Outcome of a case series. Ann
Emerg Med, 1998; 31: 124–126.
24. Böttiger BW, Bode C, Kern S et al. Efficacy and safe-
ty of thrombolytic therapy after initially unsuccess-
ful cardiopulmonary resuscitation: a prospective clin-
ical trial. Lancet, 2001; 357: 1583–1585.
25. Abu-Laban RB, Christenson JM, Innes GD et al. Tis-
sue plasminogen activator in cardiac arrest with
pulseless electrical activity. N Engl J Med, 2002; 346:
1522–1528.
26. Böttiger BW, Spöhr F. The risk of thrombolysis in
association with cardiopulmonary resuscitation – no
reason to withhold this causal and effective therapy.
J Intern Med, 2003; 253: 99–101.
27. Ruiz-Bailen M, Aguayo de Hoyos E, Serrano-Cor-
coles MC et al. Efficacy of thrombolysis in patients
with acute myocardial infarction requiring cardiopul-
monary resuscitation. Intensive Care Med, 2001; 27:
1050–1070.
28. Bozeman WP, Kleiner DM, Ferguson KL. Empiric
tenecteplase is associated with increased return of
spontaneous circulation an short term survival in car-
diac arrest atients nresponsive to standard interven-
tions. Resuscitation, 2006; 69: 399–406.
29. Lederer W, Lichtenberger C, Pechlaner C, Kroesen G,
Baubin M. Recombinant tissue plasminogen activa-
tor during cardiopulmonary resuscitation in 108 pa-
tients with out-of-hospital cardiac arrest. Resuscita-
tion 2001; 50: 71–76.
30. The European Resuscitation Council Guidelines
for Resuscitation 2005. Resuscitation, 2005; 67:
suppl. 1.
